{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:36:00Z","timestamp":1787063760999,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["8004709719"],"award-info":[{"award-number":["8004709719"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16GW0235 and 01KI2126B"],"award-info":[{"award-number":["16GW0235 and 01KI2126B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helmholtz-Zentrum f\u00fcr Infektionsforschung GmbH (HZI)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The neutropenic thigh infection model is one of the standard models in pharmacokinetic\/ pharmacodynamic (PK\/PD) characterization of novel antibacterials which are urgently needed due to the rise of antimicrobial resistance. The model enables to investigate PK\/PD parameters crucial for translation of animal results towards humans. However, the neutropenic thigh infection model can result in moderate to severe discomfort of the animals, especially when high inocula are used. Tramadol has been proven to reduce pain effectively. This study investigates if tramadol influences the bacterial burden in the primary organ, the thighs, and organs affected by secondary seeding. Therefore, several strains of the ESKAPE pathogens, namely\n                    <jats:italic>S.\u00a0aureus<\/jats:italic>\n                    ,\n                    <jats:italic>P.\u00a0aeruginosa<\/jats:italic>\n                    ,\n                    <jats:italic>K.\u00a0pneumoniae<\/jats:italic>\n                    ,\n                    <jats:italic>E.\u00a0coli<\/jats:italic>\n                    ,\n                    <jats:italic>A.\u00a0baumannii<\/jats:italic>\n                    and\n                    <jats:italic>E.\u00a0faecalis<\/jats:italic>\n                    were examined. It was shown that tramadol did not influence the bacterial burden neither in thighs nor in organs affected by secondary seeding for the strains of\n                    <jats:italic>E.\u00a0faecalis<\/jats:italic>\n                    ,\n                    <jats:italic>S.\u00a0aureus<\/jats:italic>\n                    ,\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    ,\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    and\n                    <jats:italic>E.coli<\/jats:italic>\n                    tested here, whereas secondary seeding seemed to be affected by tramadol for the tested strain of\n                    <jats:italic>A.\u00a0baumannii<\/jats:italic>\n                    . Consequently, it was demonstrated that tramadol is an option to reduce discomfort in the untreated group for the strains of five out of the six tested ESKAPE pathogens and, thereby, contributes to the refinement of one of the standard PK\/PD models.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-24111-x","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T01:13:57Z","timestamp":1668561237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Influence of tramadol on bacterial burden in the standard neutropenic thigh infection model"],"prefix":"10.1038","volume":"12","author":[{"given":"K.","family":"Rox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"24111_CR1","doi-asserted-by":"publisher","first-page":"e2013515118","DOI":"10.1073\/pnas.2013515118","volume":"118","author":"R Oldenkamp","year":"2021","unstructured":"Oldenkamp, R., Schultsz, C., Mancini, E. & Cappuccio, A. Filling the gaps in the global prevalence map of clinical antimicrobial resistance. Proc. Natl. Acad. Sci. 118, e2013515118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"24111_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0","author":"CJ Murray","year":"2022","unstructured":"Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0 (2022).","journal-title":"Lancet"},{"key":"24111_CR3","unstructured":"Antimicrobial resistance: global report on surveillance. (World Health Organization, 2014)."},{"key":"24111_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1021\/acsinfecdis.0c00044","volume":"6","author":"P Beyer","year":"2020","unstructured":"Beyer, P. & Paulin, S. The antibacterial research and development pipeline needs urgent solutions. ACS Infect. Dis. 6, 1289\u20131291 (2020).","journal-title":"ACS Infect. Dis."},{"key":"24111_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41570-021-00313-1","author":"M Miethke","year":"2021","unstructured":"Miethke, M. et al. Towards the sustainable discovery and development of new antibiotics. Nat. Rev. Chem. https:\/\/doi.org\/10.1038\/s41570-021-00313-1 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"24111_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fcimb.2019.00074","volume":"9","author":"O Fleitas Mart\u00ednez","year":"2019","unstructured":"Fleitas Mart\u00ednez, O., Cardoso, M. H., Ribeiro, S. M. & Franco, O. L. Recent advances in anti-virulence therapeutic strategies with a focus on dismantling bacterial membrane microdomains, toxin neutralization, quorum-sensing interference and biofilm inhibition. Front. Cell Infect. Microbiol. 9, 74 (2019).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"24111_CR7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40261-020-00955-x","volume":"40","author":"YR Lee","year":"2020","unstructured":"Lee, Y. R. & Yeo, S. Cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: Preclinical and clinical pharmacokinetics, pharmacodynamics efficacy and safety. Clin. Drug Investig. 40, 901\u2013913 (2020).","journal-title":"Clin. Drug Investig."},{"key":"24111_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1039\/C7NP00006E","volume":"34","author":"P Klahn","year":"2017","unstructured":"Klahn, P. & Br\u00f6nstrup, M. Bifunctional antimicrobial conjugates and hybrid antimicrobials. Nat. Prod. Rep. 34, 832\u2013885 (2017).","journal-title":"Nat. Prod. Rep."},{"key":"24111_CR9","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","volume":"24","author":"M Zhao","year":"2016","unstructured":"Zhao, M., Lepak, A. J. & Andes, D. R. Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents. Bioorg. Med. Chem. 24, 6390\u20136400 (2016).","journal-title":"Bioorg. Med. Chem."},{"key":"24111_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1128\/AAC.02352-13","volume":"59","author":"CA Rodriguez","year":"2014","unstructured":"Rodriguez, C. A., Agudelo, M., Gonzalez, J. M., Vesga, O. & Zuluaga, A. F. An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics. Antimicrob. Agents Chemother. 59, 233\u2013238 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24111_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose, P. G. et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It\u2019s not just for mice anymore. Clin. Infect. Dis. 44, 79\u201386 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"24111_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2017.09.004","volume":"36","author":"DR Andes","year":"2017","unstructured":"Andes, D. R. & Lepak, A. J. In vivo infection models in the pre-clinical pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents. Curr. Opin. Pharmacol. 36, 94\u201399 (2017).","journal-title":"Curr. Opin. Pharmacol."},{"key":"24111_CR13","first-page":"315","volume":"33","author":"FR Selbie","year":"1952","unstructured":"Selbie, F. R. & Simon, R. D. Virulence to mice of Staphylococcus pyogenes: Its measurement and its relation to certain in vitro properties. Br. J. Exp. Pathol. 33, 315\u2013326 (1952).","journal-title":"Br. J. Exp. Pathol."},{"key":"24111_CR14","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1128\/AAC.04444-14","volume":"59","author":"AJ Lepak","year":"2015","unstructured":"Lepak, A. J., Marchillo, K., Craig, W. A. & Andes, D. R. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model. Antimicrob. Agents Chemother. 59, 1258\u20131264 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24111_CR15","doi-asserted-by":"publisher","first-page":"e02388","DOI":"10.1128\/AAC.02388-19","volume":"64","author":"M Sabet","year":"2020","unstructured":"Sabet, M., Tarazi, Z. & Griffith, D. C. Pharmacodynamics of meropenem against acinetobacter baumannii in a neutropenic mouse thigh infection model. Antimicrob. Agents Chemother. 64, e02388-e2419 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24111_CR16","doi-asserted-by":"publisher","first-page":"e00078","DOI":"10.1128\/AAC.00078-20","volume":"64","author":"F Bernhard","year":"2020","unstructured":"Bernhard, F. et al. Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model. Antimicrob. Agents Chemother. 64, e00078-e120 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24111_CR17","first-page":"275","volume":"260","author":"RB Raffa","year":"1992","unstructured":"Raffa, R. B. et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an \u2018atypical\u2019 opioid analgesic. J. Pharmacol. Exp. Ther. 260, 275\u2013285 (1992).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"24111_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2125.1996.tb00152.x","volume":"41","author":"JA Desmeules","year":"1996","unstructured":"Desmeules, J. A., Piguet, V., Collart, L. & Dayer, P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br. J. Clin. Pharmacol. 41, 7\u201312 (1996).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"24111_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.biopha.2015.01.022","volume":"70","author":"M Vazzana","year":"2015","unstructured":"Vazzana, M. et al. Tramadol hydrochloride: Pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed. Pharmacother. 70, 234\u2013238 (2015).","journal-title":"Biomed. Pharmacother."},{"key":"24111_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1213\/01.ane.0000267525.51017.b8","volume":"105","author":"Z Tamanai-Shacoori","year":"2007","unstructured":"Tamanai-Shacoori, Z. et al. The antibacterial activity of tramadol against bacteria associated with infectious complications after local or regional anesthesia. Anesth. Analg. 105, 524\u2013527 (2007).","journal-title":"Anesth. Analg."},{"key":"24111_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nmni.2018.04.001","volume":"24","author":"H Farzam","year":"2018","unstructured":"Farzam, H. et al. Antibacterial effect of tramadol against Staphylococcus aureus and Pseudomonas aeruginosa: An in vivo study. New Microbes New Infect. 24, 42\u201346 (2018).","journal-title":"New Microbes New Infect."},{"key":"24111_CR22","first-page":"219","volume":"9","author":"O Unlu","year":"2021","unstructured":"Unlu, O., Bingul, E., Kesi\u0307ci\u0307, S. & Demirci, M. Investigating antimicrobial features and drug interactions of sedoanalgesics in intensive care unit: An experimental study. ADMET DMPK 9, 219\u2013226 (2021).","journal-title":"ADMET DMPK"},{"key":"24111_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1124\/dmd.105.003681","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard, N., Cresteil, T., Djebli, N. & Marquet, P. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab. Dispos. 33, 689\u2013695 (2005).","journal-title":"Drug Metab. Dispos."},{"key":"24111_CR24","doi-asserted-by":"publisher","first-page":"e10744","DOI":"10.1371\/journal.pone.0010744","volume":"5","author":"AF Zuluaga","year":"2010","unstructured":"Zuluaga, A. F., Agudelo, M., Carde\u00f1o, J. J., Rodriguez, C. A. & Vesga, O. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS ONE 5, e10744 (2010).","journal-title":"PLoS ONE"},{"key":"24111_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/378406a0","volume":"378","author":"JE Dinchuk","year":"1995","unstructured":"Dinchuk, J. E. et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378, 406\u2013409 (1995).","journal-title":"Nature"},{"key":"24111_CR26","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1096\/fj.01-0390rev","volume":"15","author":"I Tegeder","year":"2001","unstructured":"Tegeder, I., Pfeilschifter, J. & Geisslinger, G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15, 2057\u20132072 (2001).","journal-title":"FASEB J."},{"key":"24111_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.krcp.2015.10.004","volume":"34","author":"R N\u00f8rregaard","year":"2015","unstructured":"N\u00f8rregaard, R., Kwon, T.-H. & Fr\u00f8ki\u00e6r, J. Physiology and pathophysiology of cyclooxygenase-2 and prostaglandin E2 in the kidney. Kidney Res. Clin. Pract. 34, 194\u2013200 (2015).","journal-title":"Kidney Res. Clin. Pract."},{"key":"24111_CR28","doi-asserted-by":"publisher","first-page":"F1131","DOI":"10.1152\/ajprenal.00212.2007","volume":"293","author":"W Wang","year":"2007","unstructured":"Wang, W. et al. Prostacyclin in endotoxemia-induced acute kidney injury: Cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice. Am. J. Physiol.-Renal Physiol. 293, F1131\u2013F1136 (2007).","journal-title":"Am. J. Physiol.-Renal Physiol."},{"key":"24111_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10072-011-0599-z","volume":"32","author":"P Andrade","year":"2011","unstructured":"Andrade, P. et al. Role of TNF-alpha during central sensitization in preclinical studies. Neurol. Sci. 32, 757 (2011).","journal-title":"Neurol. Sci."},{"key":"24111_CR30","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17460441.2017.1377697","volume":"12","author":"L Bravo","year":"2017","unstructured":"Bravo, L., Mico, J. A. & Berrocoso, E. Discovery and development of tramadol for the treatment of pain. Expert Opin. Drug Discov. 12, 1281\u20131291 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"24111_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.vaa.2016.09.007","volume":"45","author":"R Evangelista Vaz","year":"2018","unstructured":"Evangelista Vaz, R. et al. Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. Vet. Anaesth. Analg. 45, 111\u2013122 (2018).","journal-title":"Vet. Anaesth. Analg."},{"key":"24111_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.30802\/AALAS-JAALAS-17-000118","volume":"57","author":"R Evangelista-Vaz","year":"2018","unstructured":"Evangelista-Vaz, R., Bergadano, A., Arras, M. & Jirkof, P. D. Analgesic efficacy of subcutaneous-oral dosage of tramadol after surgery in C57BL\/6J mice. J. Am. Assoc. Lab. Anim. Sci. 57, 368\u2013375 (2018).","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"24111_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00506-18","author":"JM Kidd","year":"2018","unstructured":"Kidd, J. M., Abdelraouf, K., Asempa, T. E., Humphries, R. M. & Nicolau, D. P. Pharmacodynamics of daptomycin against enterococcus faecium and enterococcus faecalis in the murine thigh infection model. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00506-18 (2018).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24111-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24111-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24111-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T01:16:15Z","timestamp":1668561375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24111-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24111"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24111-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19606"}}